The FDA last week granted regular approval to Novartis Pharmaceuticals Corp.’s Tabrecta for the treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have the mesenchymal-epithelial transition (MET) gene, a rare mutation found in about 4% of patients. The kinase inhibitor received accelerated approval in May 2020, based on positive clinical trial data. For the treatment of NSCLC, Tabrecta currently holds covered or better status for 93% of all insured lives under the pharmacy benefit. About 25% of insured lives have preferred access to Tabrecta.
SOURCE: MMIT Analytics, as of 8/17/22